HER2 Support Group Forums

HER2 Support Group Forums (https://her2support.org/vbulletin/index.php)
-   Articles of Interest (https://her2support.org/vbulletin/forumdisplay.php?f=31)
-   -   vesiculated vitamin E derivative plus pulsed dendritic cell vaccine!!! (https://her2support.org/vbulletin/showthread.php?t=23295)

Lani 04-01-2006 08:04 AM

vesiculated vitamin E derivative plus pulsed dendritic cell vaccine!!!
 
RESULTS INCREASED IL4, IL12...all of which are supposed to make herceptin more effective

still preclinical but...

1: Nutr Cancer. 2005;53(2):177-93. Links

Chemo-Immunotherapy of Breast Cancer Using Vesiculated alpha-Tocopheryl Succinate in Combination With Dendritic Cell Vaccination.

Ramanathapuram LV, Hahn T, Dial SM, Akporiaye ET.

Abstract: In this study, we evaluated the efficacy of vesiculated alpha-tocopheryl succinate (Valpha-TOS) in combination with non-antigen pulsed, nonmatured dendritic cells (nmDC) to treat pre-established tumors of the highly metastatic murine mammary cancer cell line 4T1. We demonstrated that Valpha-TOS in combination with non-antigen pulsed nmDC significantly inhibits the growth of established tumors in vivo and prolongs survival of treated mice. In addition, when initiated after resection of the established primary tumor, the combination treatment dramatically inhibits residual metastatic disease. The clinical response achieved with the combination therapy was correlated with increased interferon-gamma and interleukin-4 (IL-4) production by splenic lymphocytes and draining lymph node cells. Interestingly, when used in combination with Valpha-TOS, nmDC were as effective as tumor necrosis factor-alpha matured DC at inhibiting the growth of pre-established tumors. Valpha-TOS-induced cellular factors collected by high-speed centrifugation of supernatant from Valpha-TOS-treated tumor cells caused maturation of DC as evidenced by the up-regulation of co-stimulatory molecules and secretion of IL-12p70. These results demonstrate the potential usefulness of Valpha-TOS + DC chemo-immunotherapy in treating established primary mammary tumors as well as residual metastatic disease.

PMID: 16573379 [PubMed - in process]


All times are GMT -7. The time now is 08:18 AM.

Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021